Company: ZVRA
Filing Date: 2025-04-29
Form Type: DEFC14A
Source: 0000897069-25-000885
Chunk: 14

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-29
Form: DEFC14A
Chunk 14
---
 industry-wide backlash against opioids shortly thereafter—driven by evolving FDA standards, litigation, public health scrutiny, and political pressure. The Company’s lead asset received a Complete Response Letter (CRL), and the Company was burdened with debt incurred in preparation for a product launch that was no longer commercially viable under those new realities. Despite those overwhelming headwinds, Dr. Mickle did not walk away. He led the Company through an intense period of restructuring, secured approval for Azstarys®, and successfully negotiated a commercial partnership to extract value from the CNS pipeline. Most critically, he led a highly dilutive but necessary recapitalization that saved KemPharm from bankruptcy and gave it the ability to execute a strategic pivot into rare diseases. That pivot included the acquisition of arimoclomol—a transaction conceived, negotiated, and executed under Dr. Mickle’s leadership. The arimoclomol program ultimately resulted in the FDA’s approval of MIPLYFFA™ in 2024, the Company’s most valuable achievement to date. Reducing this history to a stock price percentage is not only intellectually dishonest—it deliberately ignores the realities of market timing, sector-wide upheaval, and the leadership required to preserve the Company through crisis. It was that leadership—Dr. Mickle’s leadership—that positioned the Company for long-term value creation. Time for Change is Now Fortunately, this year you have the power to effect change at Zevra by voting for directors of the Company other than the members of the current Board of Directors. Specifically, we offer you a choice—an ability to vote for two exceptionally qualified director nominees who have the skills and commitment to help maximize stockholder value and realize Zevra’s true potential. 10 This campaign is the result of careful consideration of the factors hampering Zevra’s potential under its current Board of Directors and lack of governance and the belief that adding the Nominees to the Board of Directors would bring sorely needed governance and be an effective contribution towards enhancing key strategic, operating and financial capabilities that would in turn improve stakeholder value. The Nominees recognize fully that as members of the Board they will owe fiduciary duties to all Zevra’s stockholders and are committed to maximizing value for all Zevra stockholders. The Proponent reserves the right to nominate additional nominees for any reason, including if the Company, by the appropriate corporate action, has increased or increases the number of directors to be elected at the Annual Meeting or the composition of the Board has changed prior to the Annual